Eli Lilly on Tuesday announced it is acquiring Point Biopharma in an effort to bolster its cancer business with the Pennsylvania-based company’s pipeline of clinical and preclinical radioligand therapies.

Amgen

The U.S. Food and Drug Administration’s staff reviewers said on Tuesday that Amgen’s late-stage study may not provide enough evidence of effectiveness for its lung cancer drug, as the company pursues a traditional approval for the treatment.

Novo Nordisk

The CEO of Novo Holdings said on Tuesday the controlling shareholder of Danish drugmaker Novo Nordisk is ready for a huge windfall from the runaway success of weight-loss drug Wegovy.

Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.

AstraZeneca

Britain’s AstraZeneca said it will pay $425 million to settle lawsuits in the United States that claimed its heartburn drugs Nexium and Prilosec caused chronic kidney disease.

Japan’s Takeda Pharmaceutical said on Monday it will voluntarily withdraw its lung cancer therapy from the United States, where it had received an accelerated approval in 2021, after it failed to meet the main goal in a late-stage study.

The U.S. Supreme Court on Monday declined to hear a lawsuit by CareDx over organ-rejection tests made by Natera and Eurofins Viracor, turning down another request to revisit the contentious issue of patent eligibility.

Novo Nordisk

The U.S. Food and Drug Administration (FDA) has approved Rivfloza (nedosiran) injection 80 mg, 128 mg, or 160 mg, a once-monthly subcutaneous ribonucleic acid interference (RNAi) therapy, to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1).

Lilly

The FDA has rejected Eli Lilly’s investigational antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis due to manufacturing problems, the company announced on Monday.

The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes.